INSIGHT. We find ourselves in a time when groundbreaking technologies such as artificial intelligence, next-generation DNA sequencing, and data-driven precision medicine rapidly reshape the healthcare landscape.
The market for AI in healthcare is projected to exceed 100 billion dollars by 2028, with an annual growth rate of over 47% compared to current levels. Innovations in DNA sequencing pave the way for data-driven precision medicine and treatments tailored specifically to each individual’s genetic profile. These advancements, bolstered by health tech and medtech innovations, aim to enhance the patient experience, optimise access to care, and streamline healthcare processes. Regarding digitalisation in healthcare, there is significant potential for change and improvement. According to a survey, digital transformation was explored by 99% of surveyed stakeholders in healthcare, while only 12% had fully implemented digital technology.
The innovations shaping the future of healthcare
Right now, healthcare is evolving faster than ever. Let’s take a closer look at what we can expect from the future of healthcare, using some Swedish life science companies as examples. Note that some of the products described are still under development.
Data-driven precision medicine enables personalised treatments
An illustrative case in the realm of data-driven precision medicine is Neogap. This biotechnology company has pioneered a distinctive approach to treating cancer based on the genetic makeup of tumours.
Since cancer arises from our cells, each cancer case is unique. Even cancer cells from the same patient and tumour can be different. This means a drug that works for one patient may not affect another. Unlike traditional cancer treatments, Neogap’s treatment is tailored to each patient and their specific tumour cells. The company’s unique technologies, PIOR® and EpiTCer®, combine AI and biotechnology to analyse the genetic composition of the tumour. Using this data, a customised treatment harnesses the patient’s T-cells to specifically target and eradicate cancer cells.
Liquid biopsy is a field within precision medicine that enables more accurate and personalised treatment strategies. Through liquid biopsy, it is possible to screen for genetic mutations, disease markers, and other molecular information from a simple blood sample or bodily fluids. SAGA Diagnostics has developed ultra-sensitive liquid biopsy tests for the early detection of cancer recurrence. The company adopts a unique approach to identify early signs of cancer recurrence better, allowing for targeted treatment interventions where they are most beneficial while avoiding over-treatment with unnecessary side effects or suffering.
Remote care on the patient’s terms
Imagine a future where you would not have to leave your home to leave a blood sample. That future is now! Medtech company Capitainer has developed innovative products for at-home blood sampling. Instead of visiting a healthcare centre, you can easily take the blood sample at home when it suits you, maintaining the same sample quality as if the sample was taken by trained medical personnel at a healthcare centre. The sample is then sent to a lab with regular mail for analysis, requiring neither refrigerated transport nor special packaging. Aligned with the growing demand for accessible and user-friendly healthcare solutions, Capitainer’s at-home self-sampling products represent a significant step toward improved remote care—on the patient’s terms.
Streamlined and optimized healthcare processes
Annually, over 300 million surgeries are performed globally, with a staggering 25% of all patients experiencing some form of complication post-operation. This is mainly because many healthcare processes do not adhere to established international guidelines. Healthtech company Encare has developed a software solution that assists hospitals in implementing best practices throughout the entire healthcare chain – from diagnosis and preparations to surgery and rehabilitation. Encare’s software supports healthcare providers in reducing the number of complications, expediting patient recovery, and consequently shortening hospital stays. This leads to significant cost savings within healthcare and ensures adherence to the highest standards of patient care.
All of the companies exemplified above are part of Sciety’s portfolio of innovative life science companies developing vital advancements in diagnostics, medicine, and healthcare. At Sciety, we will continue to monitor the life science industry, identifying the most promising companies in life science and digital health.
Interested in upcoming investment opportunities?
As a member of our Sciety Venture Partners network, you gain access to investment opportunities with the potential to contribute to a healthier society and provide solid returns. Sign up here to receive information about current offerings, company presentations, and event invitations.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.
